{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:14:39Z","timestamp":1770531279096,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Hunan Cancer Hospital Climb Plan","award":["No. QH2021009"],"award-info":[{"award-number":["No. QH2021009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-73080-w","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:02:31Z","timestamp":1727686951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of family cancer history on tumor metabolism and prognosis in patients with non-small cell lung cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Mengtian","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongpei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixiong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"1","key":"73080_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics. CA Cancer J Clin.73(1), 17\u201348 (2023). https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"73080_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71 (3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"73080_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.lungcan.2020.08.012","volume":"148","author":"L Ang","year":"2020","unstructured":"Ang, L., Chan, C. P. Y., Yau, W. P. & Seow, W. J. Association between family history of lung cancer and lung cancer risk: A systematic review and meta-analysis. Lung Cancer. 148, 129\u2013137. https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.012 (2020).","journal-title":"Lung Cancer"},{"issue":"7","key":"73080_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/CM9.0000000000001939","volume":"135","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. Associations between cancer family history and esophageal cancer and precancerous lesions in high-risk areas of China. Chin. Med. J. (Engl.)135(7), 813\u2013819. https:\/\/doi.org\/10.1097\/CM9.0000000000001939 (2022).","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"10","key":"73080_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen, P., Liu, Y., Wen, Y. & Zhou, C. Non-small cell lung cancer in China. Cancer Commun. (Lond.)42(10), 937\u2013970. https:\/\/doi.org\/10.1002\/cac2.12359 (2022).","journal-title":"Cancer Commun. (Lond.)"},{"issue":"11","key":"73080_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cac2.12099","volume":"40","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990\u20132017. Cancer Commun. (Lond.)40(11), 611\u2013619. https:\/\/doi.org\/10.1002\/cac2.12099 (2020).","journal-title":"Cancer Commun. (Lond.)"},{"issue":"1","key":"73080_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck, F. C., Boffa, D. J., Kim, A. W. & Tanoue, L. T. The eighth edition lung cancer stage classification. Chest151(1), 193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010 (2017).","journal-title":"Chest"},{"key":"73080_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2021.07.007","volume":"155","author":"Y Peters","year":"2021","unstructured":"Peters, Y. et al. Increased risk of Barrett\u2019s oesophagus and related neoplasia in individuals with a positive family history. Eur. J. Cancer. 155, 116\u2013126. https:\/\/doi.org\/10.1016\/j.ejca.2021.07.007 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"73080_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard, R. et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging42(2), 328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"73080_CR10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/cncr.26398","volume":"118","author":"L Xu","year":"2012","unstructured":"Xu, L., Li, G., Wei, Q., El-Naggar, A. K. & Sturgis, E. M. Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer118(5), 1228\u20131235. https:\/\/doi.org\/10.1002\/cncr.26398 (2012).","journal-title":"Cancer"},{"issue":"1","key":"73080_CR11","doi-asserted-by":"publisher","first-page":"10880","DOI":"10.1038\/s41598-018-28819-7","volume":"8","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Familial associations in testicular cancer with other cancers. Sci. Rep.8(1), 10880. https:\/\/doi.org\/10.1038\/s41598-018-28819-7 (2018).","journal-title":"Sci. Rep."},{"issue":"2","key":"73080_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.lungcan.2013.05.004","volume":"81","author":"Y He","year":"2013","unstructured":"He, Y. et al. Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. Lung Cancer. 81(2), 162\u2013166. https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.004 (2013).","journal-title":"Lung Cancer"},{"issue":"1","key":"73080_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell. Metab.23(1), 27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006 (2016).","journal-title":"Cell. Metab."},{"issue":"3","key":"73080_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova, N. N., Zhu, J. & Thompson, C. B. The hallmarks of cancer metabolism: Still emerging. Cell. Metab.34(3), 355\u2013377. https:\/\/doi.org\/10.1016\/j.cmet.2022.01.007 (2022).","journal-title":"Cell. Metab."},{"issue":"1","key":"73080_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1158\/1055-9965.EPI-16-0106","volume":"26","author":"CI Amos","year":"2017","unstructured":"Amos, C. I. et al. The OncoArray Consortium: A network for understanding the genetic architecture of common cancers. Cancer Epidemiol. Biomark. Prev.26(1), 126\u2013135. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0106 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"73080_CR16","doi-asserted-by":"publisher","first-page":"107272","DOI":"10.1016\/j.intimp.2020.107272","volume":"91","author":"J Tang","year":"2021","unstructured":"Tang, J., Xu, L., Zeng, Y. & Gong, F. Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4\/NF-kB signaling pathway. Int. Immunopharmacol.91, 107272. https:\/\/doi.org\/10.1016\/j.intimp.2020.107272 (2021).","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"73080_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4049\/jimmunol.2001304","volume":"207","author":"Q Pu","year":"2021","unstructured":"Pu, Q. et al. Gut microbiota regulate gut-lung axis inflammatory responses by mediating ILC2 compartmental migration. J. Immunol.207(1), 257\u2013267. https:\/\/doi.org\/10.4049\/jimmunol.2001304 (2021).","journal-title":"J. Immunol."},{"key":"73080_CR18","doi-asserted-by":"publisher","unstructured":"Dy, G. K. et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-Year analysis of CodeBreaK 100. J. Clin. Oncol. JCO2202524 (2023). https:\/\/doi.org\/10.1200\/JCO.22.02524","DOI":"10.1200\/JCO.22.02524"},{"key":"73080_CR19","doi-asserted-by":"publisher","unstructured":"Negrao, M. V. et al. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov 2023. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1420","DOI":"10.1158\/2159-8290.CD-22-1420"},{"issue":"3","key":"73080_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","volume":"29","author":"J van de Haar","year":"2023","unstructured":"van de Haar, J. et al. Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer. Nat. Med.29(3), 605\u2013614. https:\/\/doi.org\/10.1038\/s41591-023-02240-8 (2023).","journal-title":"Nat. Med."},{"issue":"1","key":"73080_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","volume":"6","author":"JK Lee","year":"2022","unstructured":"Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol.6(1), 91. https:\/\/doi.org\/10.1038\/s41698-022-00334-z (2022).","journal-title":"NPJ Precis Oncol."},{"issue":"3","key":"73080_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-20-1165","volume":"11","author":"J Carrot-Zhang","year":"2021","unstructured":"Carrot-Zhang, J. et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. Cancer Discov. 11(3), 591\u2013598. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1165 (2021).","journal-title":"Cancer Discov"},{"key":"73080_CR23","doi-asserted-by":"publisher","first-page":"752036","DOI":"10.3389\/fonc.2021.752036","volume":"11","author":"H Tan","year":"2021","unstructured":"Tan, H. et al. Glucose metabolism reprogramming of primary tumor and the liver is associated with disease-free survival in patients with early NSCLC. Front. Oncol.11, 752036. https:\/\/doi.org\/10.3389\/fonc.2021.752036 (2021).","journal-title":"Front. Oncol."},{"key":"73080_CR24","doi-asserted-by":"publisher","unstructured":"Park, S. Y., Cho, D. G., Shim, B. Y. & Cho, U. Relationship between systemic inflammatory markers, GLUT1 expression, and maximum 18F-fluorodeoxyglucose uptake in non-small cell lung carcinoma and their prognostic significance. Diagn. (Basel)13(6). https:\/\/doi.org\/10.3390\/diagnostics13061013 (2023).","DOI":"10.3390\/diagnostics13061013"},{"key":"73080_CR25","doi-asserted-by":"publisher","first-page":"1044902","DOI":"10.3389\/fonc.2022.1044902","volume":"12","author":"W Jia","year":"2022","unstructured":"Jia, W. et al. Prognostic values of ALDOB expression and (18)F-FDG PET\/CT in hepatocellular carcinoma. Front. Oncol.12, 1044902. https:\/\/doi.org\/10.3389\/fonc.2022.1044902 (2022).","journal-title":"Front. Oncol."},{"key":"73080_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.023","volume":"185","author":"R Saito","year":"2023","unstructured":"Saito, R. et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. Eur. J. Cancer. 185, 83\u201393. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.023 (2023).","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"73080_CR27","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1158\/1078-0432.CCR-18-3325","volume":"25","author":"D Planchard","year":"2019","unstructured":"Planchard, D. et al. Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. Clin. Cancer Res.25(7), 2058\u20132063. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3325 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"73080_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137 (2018).","journal-title":"N. Engl. J. Med."},{"key":"73080_CR29","doi-asserted-by":"publisher","unstructured":"Orlandi, E. et al. Unraveling the interplay of KRAS, NRAS, BRAF, and micro-satellite instability in non-metastatic colon cancer: A systematic review. Diagnostics (Basel)14(10). https:\/\/doi.org\/10.3390\/diagnostics14101001 (2024).","DOI":"10.3390\/diagnostics14101001"},{"issue":"3","key":"73080_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","volume":"76","author":"D Fogelman","year":"2015","unstructured":"Fogelman, D. et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother. Pharmacol.76(3), 489\u2013498. https:\/\/doi.org\/10.1007\/s00280-015-2788-6 (2015).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73080-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:06:21Z","timestamp":1727960781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73080-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["73080"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-73080-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol of our study was reviewed and approved by the ethics committee of The Hunan Cancer Hospical (No.23316), and the methods were carried out in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all subjects at follow-up.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"22632"}}